Exploring the Therapeutic Potential of Ganoderma lucidum in Cancer

Gabriella Cancemi,Santino Caserta,Sebastiano Gangemi,Giovanni Pioggia,Alessandro Allegra

DOI: https://doi.org/10.3390/jcm13041153

IF: 3.9

2024-02-19

Journal of Clinical Medicine

Abstract:Triterpenoids, such as ganoderic acid, and polysaccharides, including β-D-glucans, α-D-glucans, and α-D-mannans, are the main secondary metabolites of the medicinal fungus Ganoderma lucidum. There is evidence of the effects of ganoderic acid in hematological malignancies, whose mechanisms involve the stimulation of immune response, the macrophage-like differentiation, the activation of MAP-K pathway, an IL3-dependent cytotoxic action, the induction of cytoprotective autophagy, and the induction of apoptosis. In fact, this compound has been tested in twenty-six different human cancer cell types and has shown an anti-proliferative activity, especially in leukemia, lymphoma, and myeloma lines. Moreover, research clarified the capability of molecules from Ganoderma lucidum to induce mitochondrial damage in acute promyelocytic leukemia cells, without cytotoxic effects in normal mononuclear cells. Active lipids extracted from the spores of this fungus have also been shown to induce apoptosis mediated by downregulation of P-Akt and upregulation of caspases-3, -8, and -9. Among in vivo studies, a study in BALB/c mice injected with WEHI-3 leukemic cells suggested that treatment with Ganoderma lucidum promotes differentiation of T- and B-cell precursors, phagocytosis by PBMCs, and NK cell activity. Our review presents data revealing the possibility of employing Ganoderma lucidum in hematological malignancies and incorporating it into clinical practice.

medicine, general & internal

What problem does this paper attempt to address?

This paper attempts to explore the potential of *Ganoderma lucidum* in cancer treatment, particularly for hematologic malignancies such as leukemia and lymphoma. The study mainly focuses on the antitumor effects of the primary secondary metabolites in *Ganoderma lucidum*—triterpenoids (such as ganoderic acid) and polysaccharides (including β-D-glucan, α-D-glucan, and α-D-mannoglucan).

Specifically, the paper explores the therapeutic potential of *Ganoderma lucidum* through the following aspects:

1. **Inducing Apoptosis**: Polysaccharides and triterpenoids in *Ganoderma lucidum* can induce apoptosis in cancer cells, particularly by activating the mitochondrial pathway and the death receptor pathway.
2. **Stimulating Immune Response**: *Ganoderma lucidum* polysaccharides can promote the maturation of dendritic cells, enhance the proliferation of monocytic leukemia cells, and trigger the differentiation of monocytic leukemia progenitor cells into dendritic cells. Additionally, *Ganoderma lucidum* polysaccharides can increase the expression of surface markers on T cells and B cells, enhance the phagocytic activity of macrophages, and boost the activity of natural killer (NK) cells.
3. **Macrophage-like Differentiation**: Cells treated with *Ganoderma lucidum* exhibit a morphological shift from a monocytic phenotype to a macrophage-like phenotype, increasing cell adhesion. This suggests that *Ganoderma lucidum* promotes cell differentiation by activating caspase and p53 signaling pathways.
4. **Activating MAPK Signaling Pathway**: *Ganoderma lucidum* can affect cancer cell proliferation by inhibiting the ERK/MAPK signaling pathway, particularly by downregulating the phosphorylation levels of ERK1/2.
5. **Inducing Protective Autophagy**: Treatment with *Ganoderma lucidum* can induce autophagy by increasing the accumulation of LC3-II and the expression of P62/SQSTM1, thereby playing a significant role in tumor suppression.

Overall, this paper aims to reveal the potential therapeutic value of *Ganoderma lucidum* in hematologic malignancies and explore its possible clinical applications.